The global myotonic dystrophy drug market is anticipated to grow at a considerable CAGR of 7.6% during the forecast period (2022-2028). The market players in global myotonic dystrophy drug market are involved in strategic alliances like mergers & acquisitions, partnerships, business expansion, funding, and collaborations to contribute to the myotonic dystrophy makret. For instance, in April 2022, Expansion Therapeutics, received $55.3M in Series A financing for the development of therapies targeted at expanded repeat disorders, including myotonic dystrophy (DM1 and DM2). Similarly, in Dec 2021, AMO PHARMA announced their completion of two trial clinical sites in Australia and New Zealand for its pivotal REACH-CDM study evaluating the efficacy and safety of the investigational therapy AMO-02 to treat myotonic dystrophy.
Browse the full report description of “Global Myotonic Dystrophy Drug Market Size, Share & Trends Analysis Report by Drug Type (Sodium Channel Blockers, NSAIDs, Antidepressants, and Others), by Route of Administration (Oral, Intravenous), and by Distribution Channel (Online Pharmacies, Offline Pharmacies) Forecast 2022-2028” at https://www.omrglobal.com/industry-reports/myotonic-dystrophy-drug-market
Moreover, the US FDA approvals for the myotonic dystrophy drug has created lucrative opportunities in the market and has opened path for market players for the further development of novel drugs. For instance, in October 2021, FDA has granted fast track designation to AOC 1001, an investigational treatment for myotonic dystrophy. On May 3, 2021, ICREA Researcher Professor and head of the Biosensors for Bioengineering group at IBEC developed a three-dimensional model for myotonic dystrophy using bioengineering technique and patient cells. In June 07, 2021, University of Virginia School of Medicine researchers have identified new insights and potential treatment approaches for muscle loss in myotonic dystrophy.
Market Coverage
• The market number available for – 2022-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
o By Drug Type
o By Route of Administration
o By Distribution Channel
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape - ANI Pharmaceuticals, Inc., Lupin Ltd., Mylan N.V., Novartis AG, Teva Pharmaceutical Industries Ltd., and others
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Myotonic Dystrophy Drug Market Report Segment
By Drug Type
By Route of Administration
By Distribution channel
Global Myotonic Dystrophy Drug Market Report Segment by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/myotonic-dystrophy-drug-market